Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 8, 923-928, September 2006; doi:10.1634/theoncologist.11-8-923
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouzani, M.
Right arrow Articles by Nikiforakis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouzani, M.
Right arrow Articles by Nikiforakis, E.

Lymphoma

Disseminated Intravascular B-Cell Lymphoma: Clinicopathological Features and Outcome of Three Cases Treated with Anthracycline-Based Immunochemotherapy

Maria Bouzania, Themis Karmirisa, Dimitra Rontogiannib, Susanna Delimpassia, John Apostolidisa, Maria Mpakiria, Emmanuel Nikiforakisa

a Department of Hematology and Lymphoma and b Department of Histopathology, Evangelismos Hospital, Athens, Greece

Key Words. Extranodal lymphoma • Intravascular lymphoma • Immunochemotherapy

Correspondence: Maria Bouzani, M.D., Department of Hematology and Lymphoma, Evangelismos Hospital, 45-47 Ipsilandou Street, Athens 106 76, Greece. Telephone: 30-2107201103; Fax: 30-2107662850; e-mail: bouzani{at}otenet.gr

The purpose of this study was to evaluate the use of combination anthracycline-based immunochemotherapy in intravascular lymphoma (IVL). This is an extremely rare, disseminated, and aggressive extranodal CD20+ non-Hodgkin’s lymphoma (NHL) with poor outcome following anthracycline-based chemotherapy. From a population of 700 newly diagnosed patients with NHL who were registered and followed up at our unit between 1990 and 2005, three cases (0.4%) have been classified as IVL. Among the patients, there were two men and one woman, with a median age of 52 years. We have assessed the clinicopathological characteristics, response to therapy, and outcome. All patients presented with systemic symptoms and disseminated disease. All patients received anthracycline-based chemotherapy in combination with the anti-CD20 monoclonal antibody rituximab (immunochemotherapy). Complete remission was achieved in all three patients, and currently all remain progression free with a follow-up of 24–45 months. In conclusion, anthracycline-based immunochemotherapy induces durable remissions in patients with IVL, an ultimately fatal disease, suggesting that the clinical course of this disease may be altered with immunochemotherapy.




This article has been cited by other articles:


Home page
 JCOHome page
K. Shimada, K. Matsue, K. Yamamoto, T. Murase, N. Ichikawa, M. Okamoto, N. Niitsu, H. Kosugi, N. Tsukamoto, H. Miwa, et al.
Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan
J. Clin. Oncol., July 1, 2008; 26(19): 3189 - 3195.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Ishii, S. Ito, Y. Kondo, H. Tsuboi, M. Mamura, D. Goto, I. Matsumoto, A. Tsutsumi, T. Sumida, Y. Okoshi, et al.
Intravascular Large B-Cell Lymphoma With Acute Abdomen As a Presenting Symptom in a Patient With Systemic Lupus Erythematosus
J. Clin. Oncol., March 20, 2008; 26(9): 1553 - 1555.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement